159 related articles for article (PubMed ID: 19486801)
21. [Unspecific effects of certain siRNA molecules used in the treatment of age related macular degeneration].
Ebbesen M; Bek T; Pedersen FS; Jensen TG
Ugeskr Laeger; 2010 Sep; 172(36):2457-9. PubMed ID: 20825735
[TBL] [Abstract][Full Text] [Related]
22. Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.
Noël A; Jost M; Lambert V; Lecomte J; Rakic JM
Trends Mol Med; 2007 Aug; 13(8):345-52. PubMed ID: 17644433
[TBL] [Abstract][Full Text] [Related]
23. Age-related macular degeneration genetics.
Byeon SH; Chu YK
Ophthalmology; 2011 Mar; 118(3):600-1. PubMed ID: 21376244
[No Abstract] [Full Text] [Related]
24. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population.
Janik-Papis K; Zaras M; Krzyzanowska A; Wozniak K; Blasiak J; Szaflik J; Szaflik JP
Exp Mol Pathol; 2009 Dec; 87(3):234-8. PubMed ID: 19761764
[TBL] [Abstract][Full Text] [Related]
25. Analysis of SERPING1 and its association with age-related macular degeneration.
Carter JG; Churchill AJ
Acta Ophthalmol; 2011 Mar; 89(2):e212-3. PubMed ID: 19925520
[No Abstract] [Full Text] [Related]
26. [Influence of genetic mutations on clinical presentation of subretinal neovascularization. Report 2: The impact of HTRA and VEGF genes polymorphism].
Budzinskaia MV; Pogoda TV; Strelkova ID; Chikun EA; Shchegoleva IV; Kazarian ÉÉ; Galoian NS
Vestn Oftalmol; 2011; 127(4):9-16. PubMed ID: 21882634
[TBL] [Abstract][Full Text] [Related]
27. The new face of age-related macular degeneration.
Giuliari GP; Ciardella AP
Can J Ophthalmol; 2007 Aug; 42(4):629-30. PubMed ID: 17641716
[No Abstract] [Full Text] [Related]
28. Technology evaluation: pegaptanib, Eyetech/Pfizer.
Vinores SA
Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacogenetics and age-related macular degeneration, towards an individualized treatment of the disease].
Cruz-González F; Cabrillo Estévez L; López-Valverde G; Escudero-Domínguez F; González-Sarmiento R
Arch Soc Esp Oftalmol; 2013 Oct; 88(10):371-2. PubMed ID: 24060299
[No Abstract] [Full Text] [Related]
30. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.
Wong TY
Am J Ophthalmol; 2009 Sep; 148(3):327-9. PubMed ID: 19703607
[No Abstract] [Full Text] [Related]
31. Editorial: update on the modern management of wet age-related macular degeneration.
Devenyi RG
Can J Ophthalmol; 2006 Apr; 41(2):133-8. PubMed ID: 16767199
[No Abstract] [Full Text] [Related]
32. Value-based medicine.
Kymes SM; Vollman D; Frick KD
Ophthalmology; 2008 Nov; 115(11):2099; author reply 2100. PubMed ID: 19068385
[No Abstract] [Full Text] [Related]
33. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor gene polymorphisms and risk of neovascular age-related macular degeneration in a Chinese cohort.
Qu Y; Dai H; Zhou F; Zhang X; Xu X; Zhang X; Bi H; Pan X; Wang H; Jiang H; Yin N; Dang G
Ophthalmic Res; 2011; 45(3):142-8. PubMed ID: 20847577
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
36. [Electroretinography in the diagnosis and monitoring of treatment for neovascular age-related macular degeneration: Communication 2].
Zueva MV; Tsapenko IV; Riabina MV; Grinchenko MI; Neroeva NV
Vestn Oftalmol; 2009; 125(4):55-9. PubMed ID: 19824452
[TBL] [Abstract][Full Text] [Related]
37. Putting theories and results into practice: managing cases.
Nguyen QD; Do DV; Haller JA; Heier JS; Kaiser PK
Ophthalmology; 2013 May; 120(5 Suppl):S16-22. PubMed ID: 23642782
[TBL] [Abstract][Full Text] [Related]
38. [Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].
Khalaim AV; Stoliarenko GE
Vestn Oftalmol; 2007; 123(5):54-6, preceding 56. PubMed ID: 18078062
[No Abstract] [Full Text] [Related]
39. Estimating the potential impact of using intravitreal angiostatic agents for wet macular degeneration on service capacity in a large retinal referral centre.
Cheung CM; Peh KK; Yang Y
Eye (Lond); 2007 Aug; 21(8):1121-2. PubMed ID: 17525768
[No Abstract] [Full Text] [Related]
40. [VEGF in age-related macular degeneration. Part I. Physiologic and pathologic role of VEGF].
Wylegała E; Teper SJ
Klin Oczna; 2007; 109(1-3):94-6. PubMed ID: 17687924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
